A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in Subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Sponsor: Adaptimmune
Enrolling: Male and Female Patients
IRB Number: AAAS4184
U.S. Govt. ID: NCT04044768
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out if an investigational drug, called ADP-A2M4, is safe and how well it works in attacking Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (MRCLS) cancer cells. The study involves taking certain types of immune cells from the blood, called T cells, and changing them in a laboratory before putting them back into the bloodstream, with the aim of helping them to attack and kill cancer cells. It is hoped to learn if these genetically changed T cells are safe and work to kill these cancer cell types.
This study is closed
Gary Schwartz, MD
Do You Qualify?
Are you between the ages of 16 to 75? Yes No
Have you been diagnosed with advanced synovial sarcoma or myxoid liposarcoma / myxoid round cell liposarcoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator